Challenges remain in cell therapy manufacturing optimization and scalability, especially when developing autologous therapies. In a recent GEN webinar, Matthew Hewitt, PhD, head of R&D (a.i.) and ...
In 2023, the number of FDA-approved cell and gene therapies is poised to increase by more than 50%. As the number of commercially available cell therapies increases, the industry must evolve in many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results